Since ovarian cancer is a heterogeneous disease, little progress has been made in identifying a screening methodology that will improve early detection resulting in an improvement in survival. CA125 and transvaginal ultrasonography has been the mainstay of ovarian cancer screening and of primary importance in the evaluation of an adnexal mass. Despite advances in our understanding of proteomics, there have been limited advancements in the identification of biomarkers that would improve the early detection of ovarian cancer. The approval of Ova1 and HE4 has expanded our ability to help predict if a mass is benign or malignant, and how these tests should be incorporated into treatment algorithms has not been fully elucidated. Attendees of this lecture will gain awareness of how these new methodologies can be integrated with our current understanding of ovarian carcinogenesis and practice guidelines leading toward an improvement in the early detection of ovarian cancer.

For additional information about SMA and quality continuing medical education, visit our website - [ Ссылка ].

свернуть